Chronic obstructive pulmonary disease (COPD) refers to a chronic inflammatory lung disease resulting in obstructed airflow from the lungs. The recent studies conducted on analysing the efficacy of benralizumab for COPD did not show promising outcomes. This study aims to evaluate the clinical and physiological characteristics of patients with COPD, along with patients who are likely to have the greatest effect of benralizumab treatment.
This analysis of two studies – GALATHEA and TERRANOVA – included a total of 3,910 patients with moderate to very severe airflow limitation and elevated blood eosinophil counts. The researchers assessed the data for patients who received benralizumab (100 mg or 30 mg) every 8 weeks or placebo with dual or triple therapy. The primary outcome of the study was the annual exacerbation rate for benralizumab vs placebo.
Among 3,910 patients, treatment effect at 100 mg but not 30 mg occurred in 2,665 patients. The patients with treatment effect had a history of more frequent exacerbations and poorer baseline lung function. The rate ratio was 0.69 in patients who received 100 mg benralizumab and 0.86 in those who received 30 mg benralizumab.
The research concluded that patients with COPD with reductions in exacerbations experienced improved outcomes with benralizumab 100 mg.